Navigation Links
Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
Date:9/10/2007

NEW YORK, Sept. 10 /PRNewswire/ -- In a major victory for its client, Applera Corporation, a global leader in DNA sequencing technologies, Weil, Gotshal & Manges LLP won a summary judgment ruling invalidating three key contested life sciences patents. In the action, Enzo Biochem, Inc., had claimed that Applera's DNA sequencing reagents and instruments infringed the patents in question.

In a detailed 49-page Ruling, the Honorable Janet Bond Arterton of the United States District Court for the District of Connecticut concluded that the three patents were invalid for two separate reasons: first, that the patents were fatally indefinite because they fail to provide the public with adequate guidance of what is and what is not covered; and second that the patents were not novel because prior scientific publications described the same subject matter.

The case had been widely followed in the biotechnology industry because Applera's DNA sequencing reagents and instruments are core technologies enabling basic research into fundamental biological processes, as well as in applied fields such as diagnostic or forensic research.

The Weil Gotshal team was led by partners Nicholas Groombridge and Elizabeth Stotland Weiswasser. Mr. Groombridge, who late last year obtained the noteworthy trial judgment transferring inventorship and ownership of the U.S. patent that protected Imclone's blockbuster pharmaceutical, Erbitux(TM), argued the anticipation motion and commented, "We were gratified by the Court's ruling, which confirmed that these patents were not valid. When a company stands up to fight a patent, there is a clear benefit to the industry and consumers. The life sciences community, and the people and patients that it serves, owe a debt of gratitude to Applera for obtaining this win." Added Ms. Weiswasser, who argued the indefiniteness motion, "Judge Arterton's opinion carefully analyzes the patents and properly concludes that they are invalid."

About Weil, Gotshal & Manges

Weil, Gotshal & Manges LLP is an international law firm of 1,200 lawyers, including approximately 300 partners. Weil Gotshal is headquartered in New York, with offices in Austin, Boston, Budapest, Dallas, Frankfurt, Houston, London, Miami, Munich, Paris, Prague, Providence, Shanghai, Silicon Valley, Warsaw, Washington DC and Wilmington, and opening in Hong Kong in October 2007. Weil Gotshal's Intellectual Property Litigation practice was honored as the leading practice of its kind by Chambers USA with its 2007 Award of Excellence.

For more, contact: Mike Ford, Media Relations Manager

(212) 833-3999

mike.ford@weil.com

Rubenstein Associates, Rhonda Walker

212-843-8338

rwalker@rubenstein.com


'/>"/>
SOURCE Weil, Gotshal & Manges LLP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
2. Wisconsin building toward the major leagues of venture capital
3. Six things to consider before a major software implementation
4. New company eyes major ethanol production facility
5. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
6. University of Michigan plans major stem cell research center
7. BellBrook Labs gets major research funding
8. API announces major healthcare contracts
9. Top 20 big pharmas represent majority of world pharma market
10. Researchers report major advance in gene therapy technique
11. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):